adverum
biotechnologies
announces
appointment
christopher
morrison
vice
president
process
science
redwood
city
globe
newswire
adverum
biotechnologies
nasdaq
advm
gene
therapy
company
targeting
unmet
medical
needs
ocular
rare
diseases
today
announced
christopher
morrison
joined
company
vice
president
process
development
reporting
adverum
chief
technology
officer
angela
thedinga
chris
brings
wealth
aav
gene
therapy
experience
lead
commercial
manufacturing
process
said
angela
thedinga
chief
technology
officer
adverum
delighted
welcome
chris
exciting
pivotal
time
continue
execute
strategy
deliver
christopher
morrison
years
pharmaceutical
industry
experience
background
gene
therapy
recombinant
viral
vector
raav
process
development
clinical
manufacturing
recently
worked
apicbio
therapeutics
senior
director
biopharmaceutical
development
previously
worked
gemini
therapeutics
senior
director
cmc
operations
earlier
worked
voyager
therapeutics
serving
director
biopharmaceutical
development
promoted
associate
director
head
process
development
voyager
directed
development
implementation
phase
phase
manufacturing
processes
multiple
raav
products
assorted
serotypes
genomic
construct
produced
transient
production
systems
morrison
began
industry
career
pfizer
senior
scientist
promoted
principal
scientist
responsible
downstream
purification
processes
broad
range
biological
molecules
morrison
earned
doctorate
philosophy
chemical
biological
engineering
rensselaer
polytechnic
institute
bachelor
science
chemical
engineering
university
wisconsin
madison
september
company
granted
morrison
stock
option
purchase
shares
adverum
common
stock
pursuant
inducement
grant
exception
nasdaq
rule
c
inducement
material
entering
employment
adverum
option
per
share
exercise
price
equal
closing
sales
price
adverum
common
stock
nasdaq
stock
market
grant
date
vest
four
years
subject
continued
service
adverum
adverum
biotechnologies
adverum
biotechnologies
nasdaq
advm
gene
therapy
company
targeting
unmet
medical
needs
serious
ocular
rare
diseases
adverum
advancing
clinical
development
novel
gene
therapy
candidate
intravitreal
injection
treatment
patients
wet
macular
degeneration
diabetic
macular
edema
information
please
visit
statements
statements
contained
press
release
regarding
events
results
may
occur
future
statements
within
meaning
private
securities
litigation
reform
act
statements
include
limited
statements
regarding
adverum
advancements
current
clinical
trials
plans
clinical
trials
growth
expansion
process
development
capabilities
adverum
expectations
benefits
expects
addition
morrison
actual
results
could
differ
materially
anticipated
statements
result
various
risks
uncertainties
include
risks
inherent
without
limitation
adverum
novel
technology
makes
difficult
predict
time
cost
product
candidate
development
obtaining
regulatory
approval
results
early
clinical
trials
always
predictive
future
results
potential
future
complications
side
effects
connection
use
obtaining
regulatory
approval
gene
therapy
product
candidates
enrolling
patients
clinical
trials
reliance
third
parties
conducting
optic
infinity
trials
vector
production
effects
pandemic
company
operations
company
ongoing
clinical
trials
ability
fund
operations
completion
optic
infinity
trials
thereafter
risks
uncertainties
facing
adverum
described
fully
adverum
form
filed
sec
august
heading
risk
statements
contained
press
release
speak
date
made
adverum
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
investor
media
inquiries
investors
myesha
lacy
adverum
biotechnologies
media
cherilyn
cecchini
lifesci
communications
